Workshop : computational analysis and multiomics in oncology
2022-10-17 09:00 - 17:30 (Europe/Paris) | Amphithéâtre IUCT-O + MS Teams
Le lundi 17 octobre aura lieu une journée dédiée aux applications bioinformatiques en biologie lors d’un workshop intitulé « Computational analysis and multiomics in oncology » ; à l’amphithéâtre de l’IUCT-Oncopole (1 avenue Joliot-Curie, 31100 Toulouse). Ce workshop est ouvert à toute la communauté scientifique.
Cliquez ici pour consulter le programme.
On monday, october 17, a day dedicated to bioinformatics applications in biology will take place during a workshop entitled « Computational analysis and multiomics in oncology »; at the IUCT-Oncopole auditorium (1 avenue Joliot-Curie, 31100 Toulouse). This workshop is open to the whole scientific community.
Click here to consult the programme

Cliquez ici pour accéder à la visioconférence MS Teams.
Précision : en visio cela sera de la diffusion seulement, pas d’interaction possible à cause de la mise à jour du système de l’amphi qui n’est pas encore faite. Donc le présentiel reste à privilégier pour l’interaction.

Conférence Dr Nicolas Fraunhoffer : Multiomics integration unravels new therapeutic targets and pathobiological mechanisms in pancreatic cancer
2022-10-28 11:00 - 12:00 | Salle Cazaux + Visio Teams
Cliquez ici pour accéder à la visioconférence MS Teams.

Soutenance de thèse : Nathan Guiraud (équipe METAML)
2022-12-06 14:00 - 17:00 | Amphithéâtre IUCT-O + MS Teams
Soutenance de thèse de Nathan Guiraud Phd équipe METAML – Les cellules souches leucémiques : De l’origine des leucémies aigües myéloïdes à la prochaine révolution thérapeutique
Amphithéâtre de l’IUCT-o et sur Teams
Participer sur votre ordinateur ou votre application mobile
Cliquez ici pour participer à la réunion

Conférence : Building a barrier to replication fork degradation with Okazaki fragment, Dr Sarah Lambert (Institut Curie)
2023-01-13 11:00 - 12:00 | Salle Cazaux + Visio Teams

Conférence : Lessons from the melanoma ecosystem, Pr Florian Rambow
2023-02-03 11:00 - 12:00 | Salle Cazaux + Visio Teams

Insights into the disruption of gene regulatory programs in cancers. Présentée par le Dr Anthony Mathelier (Molecular Medicine Norway Center, Oslo)
2023-03-10 11:00 - 12:00 | Salle Cazaux + Visio Teams
Lien vers la visioconférence

Conférence CRCT - Epithelial memory of inflammation can be by-passed through Vps34 inactivation to limit cancer initiation. Présenté par Dr Julie Guillermet-Guibert (équipe SigDyn)
2023-03-17 11:00 - 12:00 | Salle Cazaux + Visio Teams
Conférence CRCT -Epithelial memory of inflammation can be by-passed through Vps34 inactivation to limit cancer initiation. Présenté par Dr Julie Guillermet-Guibert (équipe SigDyn)

Salle Cazaux + visio Teams
Lien vers la Conférence Teams

Conférence : Different modelling strategies to suggest personalized treatments to cancer patients. Présentée par Dr Laurence Calzone, Institut Curie
2023-03-21 10:00 - 11:00 | Salle Cazaux + Visio Teams

Oncogenic pathways in cancer workshop
2023-03-31
Découvrez ici les abstracts de tous les intervenants.
Lien vers la conférence Teams

Conférence | Comment l'environnement social et les déterminants sociaux influencent le risque de cancer, sa prise en charge et son évolution | Dr Sébastien Lamy (CERPOP/IUCT)
2023-04-21 11:00 - 12:00 | Salle Cazaux + Visio Teams

Workshop axe 2 "RNA & cancer"
2023-05-12 | Amphithéâtre IUCT-O

Conférence | Understanding and predicting the role of the immune microenvironment in lung adenocarcinoma | Dr Michaël Kammer
2023-06-02 11:00 - 12:00 | Salle Cazaux + Visio Teams
Lien vers la retransmission MS Teams

Conférence | Metabolic plasticity in ovarian cancer: a new therapeutic opportunity? | Pr Francesc Viñals
2023-06-09 11:00 - 12:00 | Salle Cazaux + Visio Teams

Conférence | Multimodal data integration for genetic diseases | Dr Anaïs Baudot
2023-06-16 11:00 - 12:00 | Salle Cazaux + Visio Teams

Conférence | Multiscale in silico modeling of life | Dr David Simoncini et Dr Sylvain Cussat-Blanc
2023-06-23 11:00 - 12:00 | Salle Cazaux + Visio Teams
Lien vers la retransmission vidéo sur MS Teams

Conférence | Self-organizing principles driving tumor stemness and hierarchy | Carlos Pérez-González (Institut Curie)
2023-06-28 13:30 - 14:30 | Salle Cazaux + Visio Teams
Colorectal tumors are heterogeneous and hierarchical. Tumor growth relies on the proliferation of cancer stem cells, which constantly produce non-proliferative differentiated cells that eventually die. Despite this hierarchy, treatments targeting cancer stem cells often fail at eradicating the tumor, because the remaining cancer cells dedifferentiate to replenish the stem cell pool. It is thus crucial to understand which factors compose the tumor stem cell niche to induce cancer stemness. While most research focuses on niche factors produced by the stroma, we studied the appearance of stem cells in tumor organoids cultured in the absence of niche factors. In these minimal conditions, stem cells spontaneously appear at the center of the organoid after 3 days in culture. Physical confinement of the organoid boosts the appearance of stem cells, showing that stemness can be mechanically induced by cell crowding. Furthermore, while small organoids mostly contain cancer stem cells after 5 days of culture, large organoids position the stem cell niche at the organoid edge and develop a differentiated area in the center. These organoids establish a functional hierarchy: stem cells proliferate at the edge, migrate towards the organoid center, differentiate, and die. This spatial distribution of cell types and functions is strikingly similar to that observed in real tumors. Our results show that cancer cells have an intrinsic ability to generate a stem cell niche in the absence of external signals and that there is a critical size to establish a functional hierarchy. Further experiments will reveal the molecular mechanisms governing these self-organizing principles, as well as their contribution to tumor progression.
References:
Pérez-González C*, Ceada G* et al. Mechanical compartmentalization of the intestinal organoid enables crypt folding and collective cell migration. Nat Cell Biol 23, 745–757 (2021).
Barbazan J*, Pérez-González C* et al. Cancer-associated fibroblasts actively compress cancer cells and modulate mechanotransduction. bioRxiv 2021.04.05.438443 (2021).
Pérez-González C*, Alert R* et al. Active wetting of epithelial tissues. Nat. Phys. 15, 79–88 (2019).

Lien vers la retransmission MS Teams

Conférence | Mechanical forces and microenvironment heterogeneity promote leukemic stem cell resistance | Dr Sylvain Lefort | CRCL, Lyon
2023-09-22 11:00 - 12:00 | Salle Cazaux + Visio Teams
Lien vers la visioconférence

Abstract :
In myeloid leukaemias, the rapid clonal expansion of leukemic cells in the bone marrow leads to alterations of microenvironment properties, and reduction of the overall availability for each cell type in the constrained space of the medullar niche. In addition, bone marrow fibrosis that often occurs in myeloid leukemias induces physical modifications of the microenvironment. Reciprocally, the leukemic niche through a symmetrical mechanic response can also affect the intrinsic stiffness of leukemic cells. Therefore, our goal is to understand how leukemic bone marrow microenvironment can support leukemic progression or alter treatment response in myeloid malignancies. For this purpose, we use a standardized 3D human co-culture model, which allows maintenance of hematopoietic stem cells capacities, to track CML leukemic stem cells dormancy upon treatment. In addition, we have identified that resistant AML cells harbors different intrinsic rigidities and mechanotransduction pathways activation compared to sensitive cells. Our current strategy includes study of the interplay between leukemic cells and extracellular matrices of different natures (composition and stiffness) and usage of a soft cell confinement system.
Selected Publications:
– Voeltzel T*, Fossard G, Degaud M, Geistlich K, Gadot N, Jeanpierre S, Mickaelian I, Brevet M, Anginot A, Le Bousse-Kerdiles MC, Trichet V, Lefort S*, Maguer-Satta V*. A minimal standardized human bone marrow microphysiological system to assess resident cell behavior during normal and pathological processes. Biomaterials Science. 2022 Jan 18;10(2):485-498.
– Lefort S, El-Naggar A, Tan S, Colborne S, Negri GL, Pellacani D, Hirst M, Gusterson B, Morin GB, Sorensen PH, Eaves CJ. De novo and cell lines models of human mammary cell transformation reveal an essential role for Yb-1 in multiple stages of human breast cancer. Cell Death Differ. 2022 Jan; 29(1):54-64.
– Jeanpierre S, Arizkane K, Thongjuea S, Grockowiak E, Geistlich K, Barral L, Voeltzel T, Guillemin A, Gonin-Giraud S, Gandrillon O, Nicolini FE, Mead A, Maguer-Satta V*, Lefort S*. The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission. Haematologica. 2021 Jan 1 ;106(1) :111-122.
– Prunet A, Lefort S, Delanoë-Ayari H, Laperrousaz B, Simon G, Saci S, Argoul F, Guyot B, Rieu J-P, Gobert S*, Maguer-Satta V*, Rivière C*. Development of a soft cell confiner to decipher the impact of mechanical stimuli on cells. Lab Chip. 2020 Nov 7 ;20(21) :4016-4030
– Bulaeva E, Pellacani D, Nakamichi N, Hammond C.A, Beer P.A, Lorzadeh A, Moksa M, Carles A, Bilenky M, Lefort S, Shu J, Wilhelm B.T, Weng A.P, Hirst M, Eaves C.J. MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus. Blood. Dec 10 ;136(24) :2764-2773.
– Lefort S*, Balani S, Pellacani D, Guyot B, Gorski SM, Maguer-Satta V, Eaves CJ. Monitoring autophagy heterogeneity in normal and de novo transformants of human mammary cells. Sci Rep. 2020 Nov 20 ;10(1) :20266
– Lefort S*, Tan S, Balani S, Rafn B, Hirst M, Eaves CJ. Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation. Oncogene. 2019 Nov 26.
– Voeltzel T, Flores-Violante M, Zylbersztejn F, Lefort S, Billandon M, Jeanpierre S, Joly S, Fossard G, Milenkov M, Mazurier F, Nehme A, Belhabri A, Paubelle E, Thomas X, Michallet M, Louache F, Nicolini FE, Caron de Fromentel C, Maguer-Satta V. A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome. Cell Death Dis. 2018 Sep 27;9(10):1011.
– Lefort S, Thuleau A, Kieffer Y, Sirven P, Bieche I, Marangoni E, Vincent-Salomon A, Mechta-Grigoriou F. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancers patients. Oncogene 2017 Mar 2;36(9):1211-1222. doi: 10.1038.
– Nguyen LV*, Pellacani D*, Lefort S, Kannan N, Osako T, Makarem M, Cox CL, Kennedy W, Beer P, Carles A, Moksa M, Bilenky M, Balani S, Babovic S, Sun I, Rosin M, Aparicio S, Hirst M, Eaves CJ. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. Nature. 2015 Dec 10; ;528(7581):267-71.
– Lefort S*, Joffre C*, Kieffer Y, Givel AM, Bourachot B, Zago G, Bieche I, Dubois T, Meseure D, Vincent-Salomon A, Camonis J, Mechta-Grigoriou F. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy. 2014;10(12):2122-42.
Mini Bio:
Tout au long de mes travaux de recherche, j’ai cherché à identifier des mécanismes intrinsèques et extrinsèques essentiels à l’homéostasie, à l’initiation et la progression tumorale. Ainsi durant mon PhD (2005-2009), j’ai identifié des mécanismes consécutifs à l’infection par KSHV permettant l’établissement de la pathologie et de la tumorigénèse. J’ai ensuite rejoint l’Institut Curie (2009-2013), où mes travaux ont permis d’identifier des cibles thérapeutiques tumorales ou microenvironnementales spécifiques de sous−types de cancer du sein. Au sein du laboratoire Terry Fox (2014-2017), mes travaux sur les cellules souches et progénitrices mammaires humaines ont permis d’étudier le rôle de plusieurs déterminants moléculaires, tels que YB−1 et YAP, impliqués dans l’initiation tumorale. Ayant rejoint le CRCL en 2017, je m’intéresse dorénavant au rôle des contraintes mécaniques, via les éléments mécanosenseurs BMP et YAP, dans le maintien des cellules souches hématopoïétiques et leucémiques via leur interaction avec leur microenvironnement.

Workshop Post-doctorants
2023-10-05 | Amphithéâtre IUCT-O
Plus d’informaitons : https://www.crct-inserm.fr/en/ys2c_gso/

Soutenance de thèse de Sebastian Castillo (Equipe Signather)
2023-10-09 09:00 - 11:00 | Salle Cazaux + Visio Teams
Intitulé de la thèse :
Regulation of the ERK/MAPK signaling pathway by the small GTPase RHOB in non-small-cell lung cancer

Pour suivre la soutenance de thèse à distance, cliquez ici.

Conférence : BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas | Marie Castets, CRCL
2023-10-13 11:40 - 12:10 | Salle Cazaux + Visio Teams
Important : reportée de 11h40 à 12h10
Pour suivre la conférence à distance, cliquez ici.
Abstract :
Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably with the identification of K27M mutations in histone H3. However, the synergistic oncogenic mechanisms that induce and maintain tumor cell phenotype have yet to be deciphered.
In 20 to 30% of cases, these tumors have an altered BMP signaling pathway with an oncogenic mutation on the BMP type I receptor ALK2, encoded by ACVR1. However, the potential impact of the BMP pathway in tumors non-mutated for ACVR1 is less clear. By integrating bulk, single-cell and spatial transcriptomic data, we show here that the BMP signaling pathway is activated at similar levels between ACVR1 wild type and mutant tumors and identify BMP2 and BMP7 as putative activators of the pathway in a specific subpopulation of cells. By using both pediatric isogenic glioma lines genetically modified to overexpress H3.3K27M and patients-derived DIPG cell lines, we demonstrate that BMP2/7 synergizes with H3.3K27M to induce a transcriptomic rewiring associated with a quiescent but invasive cell state. These data suggest a generic oncogenic role for the BMP pathway in gliomagenesis of pDMG and pave the way for specific targeting of downstream effectors mediating the BMP/K27M crosstalk.

Publication shortlist :
Modeling the next-generation of fusion-negative rhabdomyosarcoma 3D-organoids to predict effective drug combinations: a proof-of-concept on cell death inducers. Clara Savary, Paul Huchedé, Léa Luciana, Arthur Tourbez, Clémence Deligne, Cécile Picard, Thomas Diot, Claire Coquet, Nina Meynard, Marion Le Grand, Laurie Tonon, Nicolas Gadot, Cyril Degletagne, Sophie Léon, Valéry Attignon, Alexandra Bomane, Isabelle Rochet, Kevin Müller, Virginie Mournetas, Christophe Bergeron, Paul Rinaudo, Aurélie Dutour, Martine Cordier-Bussat, Frédérique Dijoud, Nadège Corradini, View ORCID ProfileDelphine Maucort-Boulch, Eddy Pasquier, View ORCID ProfileJean-Yves Blay, Marie Castets*, Laura Broutier*. In revision, Cell Reports Medicine. Available on Biorxiv.
BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas. Paul Huchedé, Swann Meyer, Clément Berthelot, Maud Hamadou, Adrien Bertrand-Chapel, Andria Rakotomalala, Line Manceau, Julia Tomine, Nicolas Lespinasse, Paul Lewandowski, Martine Cordier-Bussat, Laura Broutier, Aurélie Dutour, Isabelle Rochet, Jean-Yves Blay, Cyril Degletagne, Valéry Attignon, Angel Montero-Carcaboso, Marion Le Grand, Eddy Pasquier, Alexandre Vasiljevic, Pascale Gilardi-Hebenstreit, Samuel Meignan, Pierre Leblond, Vanessa Ribes, Erika Cosset, Marie Castets. eLife, in press. Available on Biorxiv.
The TLR3 L412F polymorphism prevents TLR3-mediated tumor cell death induction in pediatric sarcomas. Bisaccia J, Meyer S, Bertrand-Chapel A, Hecquet Q, Barbet V, Kaniewski B, Léon S, Gadot N, Rochet I, Fajnorova I, Leblond P, Cordier-Bussat M, Corradini N, Vasiljevic A, Billaud M, Picard C, Broutier L, Gallerne C, Dutour A, Blay JY, Castets M. Cell Death Discov. 2023 Jul 7;9(1):230. doi: 10.1038/s41420-023-01513-y. PMID: 37414800
Holistic pediatric oncology: towards a second Copernican revolution. André N, Castets M, Pasquier E, Mehlen P. Trends Cancer. 2023 Sep;9(9):693-696.
The Intricate Epigenetic and Transcriptional Alterations in Pediatric High-Grade Gliomas: Targeting the Crosstalk as the Oncogenic Achilles’ Heel. Huchedé P, Leblond P, Castets M. Biomedicines. 2022 Jun 3;10(6):1311. doi: 10.3390/biomedicines10061311. PMID: 35740334
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death. Vial J, Royet A, Cassier P, Tortereau A, Dinvaut S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, Depaepe L, Pantalacci S, de la Fouchardière A, Micheau O, Dalle S, Laudet V, Mehlen P, Castets M. Cell Death Differ. 2019 Mar;26(3):443-454. doi: 10.1038/s41418-018-0128-1. Epub 2018 May 31. PMID: 29855541
Mini Bio
Marie Castets, PhD
Chef de l’équipe « Mort cellulaire et cancers pédiatriques » au Centre de Recherche en cancérologie de Lyon, CRCL, Centre Léon Bérard, Lyon, elle est aussi à l’origine du réseau national React4Kids lancé en 2018, et qui réunit actuellement l’ensemble des scientifiques français développant des axes de recherche fondamentale et translationnelle en cancérologie pédiatrique.
« Face à la complexité du cancer, il n’y a qu’en mutualisant nos expertises et nos outils que nous parviendrons à améliorer de manière significative la prise en charge des patients. Et si cette collaboration doit évidemment se faire au niveau international, il convient de s’appuyer sur une forte structuration nationale pour avancer de manière efficace dans la compréhension des mécanismes moléculaires impliqués dans les cancers pédiatriques. C’est l’objectif du réseau national de recherche fondamentale et translationnelle React4Kids, lancé en 2018 avec une dizaine de chercheurs et qui compte aujourd’hui plus de 380 membres. »
Elle pilote également depuis 2020 la plateforme Share4Kids, dont l’objectif est de mettre à disposition de la communauté scientifique des données multi-omiques de qualité en open-access sur les cancers des enfants.

Conférence | Insights into the disruption of gene regulatory programs in cancers | Dr Anthony Mathelier
2023-10-20 11:00 - 12:00 | Salle Cazaux + Visio Teams
Pour suivre la conférence à distance, cliquez ici.
Abstract:
Most cancer somatic alterations occur in the noncoding portion of the human genome, which contains important cis-regulatory regions acting as genetic switches to ensure gene expression occurs at correct times and intensities in correct tissues. However, the identification of critical noncoding cancer driver events has been mostly limited to a few examples with high recurrence or high functional impact. Transcription factors (TFs) are key proteins binding to cis-regulatory regions at their TF binding sites to modulate the rate of gene transcription. As cancer is a disease of disrupted cellular regulation, it is critical to analyze these regions to highlight patient somatic mutations and epigenetic modifications altering the gene regulatory program of the cells. In this talk, I will present our recent works on the interplay between TF binding, somatic mutations, and DNA methylation alteration that shifts the gene regulatory program in patients cancer cells.

Séminaire Jeunes Chercheurs du Labex Toucan
2023-10-26 14:00 - 17:00 | Amphithéâtre IUCT-O

Workshop axe 3 Microenvironnement tumoral et métabolisme
2023-11-09 09:00 - 13:00 | Amphithéâtre IUCT-O
Cliquez ici pour découvrir les abstracts des intervenants.

Conférence : Patient trajectories derived from synchronic clinical datasets | Andrei Zinovyev, Evotec
2023-11-17 11:00 - 12:00 | Salle Cazaux + Visio Teams
Pour suivre la conférence à distance, cliquez ici.
Abstract:
The concept of patient trajectory is important in understanding a disease as a dynamic process that evolves over time. Evaluating patient trajectories typically involves longitudinal (diachronic) datasets, which are still relatively scarce and expensive. Drawing from the concepts of pseudotime and the ergodic principle in single-cell data science, we recently introduced a methodology for quantifying hypothetical stereotypical patient trajectories from synchronic (snapshot) clinical datasets. These trajectories characterize the landscape of all possible disease conditions, illustrating how a specific disease state develops along stereotypical routes, marked by « points of no return » and « final states » such as lethal or recovery states. We demonstrate how applying this methodology yields insights from extensive clinical datasets in cardiology and COPD, which can be used to enhance these diseases management.
Short bio:
Andrei Zinovyev has a background in computational biology and machine learning, focusing on developing new methods and algorithms for modeling and analyzing biological data. After completing a 3-year postdoc at the Institute des Hautes Études Scientifiques (the French counterpart of the Advanced Studies), he transitioned to the Institut Curie, where he co-founded the « Computational Systems Biology of Cancer » research group, which he co-led for 18 years. In 2019, Andrei got a chair at the Paris Artificial Intelligence Research Institute, focusing on the application of machine learning to multiomics and clinical data. In 2022, he made the switch to industrial research in the role of Principal Scientist at Evotec in Toulouse in the In silico R&D department.

WORKSHOP : Clinical applications of PI3K inhibitors
2024-01-11 09:30 - 15:45 | Amphithéâtre IUCT-O + MS Teams
Speakers:
Michael LAHN, Mariona GRAUPERA, Emilio HIRSCH+ others
Lien Teams :
Programme

Formation qPCR
2025-01-23 09:30 - 16:30 | Salle Cazaux
Organisé par Carine Valle et Emeline Sarot
carine.valle@inserm.fr / emeline.sarot@inserm.fr

Stand Société Selleck Chemicals
2025-02-06 09:00 - 13:00 | Espace détente 1er étage
Présentation de produits et offres
Intervenants : Esther Marque, Brian Donegan

Soutenance de thèse : Intérêt de l'ADN tumoral circulant dans la prise en charge de l'adénocarcinome pancréatique résécable - Charlotte Maulat, ImPACT/CHU Toulouse
2025-02-28 14:00 - 17:00 | salle du conseil de la faculté de médecine au 32 allées Jules Guesdes

Conférence - Anna Niarakis, CBI
2025-03-14 11:00 - 12:00 | Salle Cazaux
Dr Anna Niarakis is now a Full Professor of Computational Systems Biology at the University of Toulouse III-Paul Sabatier, affiliated with the Center of Integrative Biology and the Laboratory of Molecular, Cellular and Developmental Biology. She was previously an Associate Professor at the University of Evry, Paris Saclay, and an INRIA Saclay delegate.
She has a broad scientific background in Biochemistry, Biology, Pharmaceutical Technology and post-doctoral studies in Computational Systems Biology and Bioinformatics (ENS, Paris, Institut Gustave Roussy) with expertise in complex human diseases, especially autoimmune diseases. She is a co-leader of the Disease Maps consortium and leads the Working Group “ Building Immune Digital Twins”, supported by the Research Data Alliance.
Google scholar: https://scholar.google.ch/citations?user=bpOOfdMAAAAJ&hl=en
LinkedIn: https://www.linkedin.com/in/anna-niarakis-58535b3/

Séminaire technologique - Felipe Oliveira, Navinci
2025-03-20 10:00 - 11:00 | Salle Cazaux
Dr. Felipe Oliveira is a Field Application Specialist at Navinci; with over 10 years of experience in varying forms of proximity ligation assays. He completed his PhD in the lab of Prof. Masood Kamali-Moghaddam in 2018, where he developed and applied variations of proximity assays for detection of single biomarker, complex protein, as well as PTMs. He holds a PhD in molecular medicine and molecular tools development from Uppsala University and a BSc in molecular biology from Emory University.
Pour en savoir plus sur le séminaire technologique, cliquez ici
